国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
13期
1955-1957
,共3页
赵光日%戴璐%杨新彬%周明
趙光日%戴璐%楊新彬%週明
조광일%대로%양신빈%주명
晚期肺腺癌%小剂量%吉西他滨%顺铂%时序用药%疗效观察
晚期肺腺癌%小劑量%吉西他濱%順鉑%時序用藥%療效觀察
만기폐선암%소제량%길서타빈%순박%시서용약%료효관찰
Advanced lung cancer%Small doses%Gemcitabine%Capsulation%Timing of medication%Efficacy
目的 探讨临床中晚期肺腺癌患者应用小剂量吉西他滨与顺铂时序用药治疗效果.方法 选取我院2009年1月至2009年12月80例晚期肺腺癌患者为研究对象,将其按照随机数字法分为研究组和对照组,研究组给予小剂量吉西他滨与顺铂时序用药治疗,对照组给予小剂量吉西他滨与顺铂常规用药治疗,观察两组的治疗效果.结果 研究组治疗有效率为65.0％,对照组治疗有效率为42.5％,研究组治疗有效率明显的高于对照组,差异有统计学意义(P＜0.05).研究组骨髓抑制、血小板减少和粒细胞减少以及周围神经损害与恶心、呕吐发生率均明显的低于对照组,差异有统计学有意义(P＜0.05).研究组和对照组1年后的生存率分别为72.5％、70.0％,两组的数据比较差异无统计学意义(P＞0.05);研究组和对照组3年后生存率分别为52.5％、27.5％,两组的数据比较差异有统计学意义(P＜0.05).结论 临床中对于晚期肺腺癌患者应用小剂量吉西他滨与顺铂联合治疗采取时序用药治疗效果显著,毒副反应少,值得临床中应用与推广.
目的 探討臨床中晚期肺腺癌患者應用小劑量吉西他濱與順鉑時序用藥治療效果.方法 選取我院2009年1月至2009年12月80例晚期肺腺癌患者為研究對象,將其按照隨機數字法分為研究組和對照組,研究組給予小劑量吉西他濱與順鉑時序用藥治療,對照組給予小劑量吉西他濱與順鉑常規用藥治療,觀察兩組的治療效果.結果 研究組治療有效率為65.0％,對照組治療有效率為42.5％,研究組治療有效率明顯的高于對照組,差異有統計學意義(P＜0.05).研究組骨髓抑製、血小闆減少和粒細胞減少以及週圍神經損害與噁心、嘔吐髮生率均明顯的低于對照組,差異有統計學有意義(P＜0.05).研究組和對照組1年後的生存率分彆為72.5％、70.0％,兩組的數據比較差異無統計學意義(P＞0.05);研究組和對照組3年後生存率分彆為52.5％、27.5％,兩組的數據比較差異有統計學意義(P＜0.05).結論 臨床中對于晚期肺腺癌患者應用小劑量吉西他濱與順鉑聯閤治療採取時序用藥治療效果顯著,毒副反應少,值得臨床中應用與推廣.
목적 탐토림상중만기폐선암환자응용소제량길서타빈여순박시서용약치료효과.방법 선취아원2009년1월지2009년12월80례만기폐선암환자위연구대상,장기안조수궤수자법분위연구조화대조조,연구조급여소제량길서타빈여순박시서용약치료,대조조급여소제량길서타빈여순박상규용약치료,관찰량조적치료효과.결과 연구조치료유효솔위65.0％,대조조치료유효솔위42.5％,연구조치료유효솔명현적고우대조조,차이유통계학의의(P＜0.05).연구조골수억제、혈소판감소화립세포감소이급주위신경손해여악심、구토발생솔균명현적저우대조조,차이유통계학유의의(P＜0.05).연구조화대조조1년후적생존솔분별위72.5％、70.0％,량조적수거비교차이무통계학의의(P＞0.05);연구조화대조조3년후생존솔분별위52.5％、27.5％,량조적수거비교차이유통계학의의(P＜0.05).결론 림상중대우만기폐선암환자응용소제량길서타빈여순박연합치료채취시서용약치료효과현저,독부반응소,치득림상중응용여추엄.
Objective To evaluate the clinical application of advanced lung cancer patients with small doses of gemcitabine and capsulation timing of drug treatment.Methods In our hospital from January 2009 to December 2009,80 patients with advanced lung cancer patients were selected for the study,they were randomly divided into study group and control group,study group was given a small dose of gemcitabine and capsulation timing of medication treatment,the control group was given a small dose of gemcitabine and capsulation with conventional drug treatment,the treatment effects were observed in both groups.Results The response rate was 65.0％ in the treatment group,higher than that of the control group (42.5％),showing statistical significant difference (P ＜ 0.05).Study group' s myelosuppression,thrombocytopenia and neutrogena and peripheral nerve damage and nausea and vomiting were significantly lower than those of the control group,with statistical significant difference (P ＜ 0.05).l-year survival rates of study group and the control group were 72.5％,70.0％ respectively,showing no significant difference (P ＞ 0.05); three-year survival rates of study group and the control group were 52.5％ and 27.5％ respectively,showing statistical significant difference (P ＜ 0.05).Conclusion For clinical application of advanced lung cancer patients a small dose of gemcitabine and capsulation combination therapy taking medication timing has significant treatment effect,with less adverse reaction,which is worthy of clinical application and promotion.
